(This article isTMT Pro (Professional Edition)(For user exclusive use)
"TMT Post Pro Weekly Report" aggregates domestic and international financing events and hotspots of the week through TMTBase, the global primary market database of TMT Post. It aims to enable investors and entrepreneur users to clearly understand trends, grasp investment logic, and seize the latest industry opportunities in a time and data-intensive manner.
Industry Report Catalog
The full report contains 4,984 words and 6 illustrations.
1. Key Industry Overview
2. Primary Market Dynamics
2.1, Financing Dynamics in China Over the Past Week (Figure: Details/Fields/Stages of Financing Projects)
2.2, Project Recommendation by Titanium Media Pro in China
2.3, Overseas Weekly Financing Dynamics (Figure: Financing Project Details/Field/Stage)
2.4, Overseas Titanium Media Pro·Project Recommendation
3. Industry Observation
4. Industry Policy
For project exposure, please send project materials to: tmtpro@tmtpost.com
Key Reading Points
A total of 40 global investment and financing projects in the medical and health field were recorded, including 18 domestic financings and 22 overseas financings. In terms of financing areas, there were 6 investment and financing projects in China's medical device and hardware sector, ranking first, and 5 projects in the medical informatization sector, ranking second; overseas, there were 8 investment and financing projects in the pharmaceuticals sector, ranking first, and 6 projects in the medical informatization sector, ranking second.
In terms of domestic investment and financing, in the pharmaceutical field, "Grit Biotechnology," which focuses on tumor immunotherapy, has completed a 400 million yuan B-round financing; in the biotechnology field, synthetic biology company "Cotio Bio" has completed an over 100 million yuan A-round financing.
In terms of overseas investment and financing in the pharmaceutical field, the British biopharmaceutical company "Apollo Therapeutics" raised $226.5 million in its Series C financing round, while the small molecule drug development platform "Nimbus Therapeutics" completed a $210 million private placement.
From September 4, 2023, to September 10, 2023, the TMTBASE global primary market database of Titanium Media recorded a total of 40 financing events in the healthcare track at home and abroad, including 18 domestic financings and 22 overseas financings.
China Weekly Financing Dynamics
✔. In the past week, the TMTBASE global primary market database of Titanium Media recorded 18 financing events in the medical and health field in China, a 43.75% decrease from the previous week.
✔. In terms of the number of financings, there were 6 investment and financing activities in the medical device and hardware field, 5 in the medical informatization field, 4 in the pharmaceuticals field, 2 in the biotechnology field, and 1 in the medical services field.
✔. In terms of financing rounds, there were 4 angel rounds, 2 Pre-A rounds, 2 A rounds, 1 A++ round, 2 B rounds, 2 C+ rounds, 8 equity investments, and 1 merger and acquisition.
✔. There were 4 disclosed projects with financing amounts exceeding RMB 100 million in the past week, coming from the fields of medical devices and hardware, pharmaceuticals, biotechnology, and medical informatization.
Recommended Projects by Titanium Media Pro in China
Pharmaceuticals
"Shale Bio" Completes RMB 400 Million Series B Financing
Recently, "Grit Biotechnology" announced the completion of a 400 million RMB Series B financing round. This round was led by a fund under CICC Capital, with follow-on investments from Qianhai Ark, Liantong Investment, Yuanhe Capital, Hefangtian Partnership, as well as existing shareholders Sherpa Healthcare Partners, Decheng Capital, and Matrix Partners China.
The main purpose of this financing is to support the development of Grail Bio's tumor-infiltrating lymphocyte (TIL) therapy pipeline. The company plans to use the funds for the pivotal clinical trial of GT101 and the development of the next-generation gene-edited TIL pipeline. Grail Bio is committed to providing groundbreaking cell therapy drugs for patients with solid tumors worldwide.
Grit Bio was founded in 2019 as an innovative pharmaceutical company focused on tumor immunotherapy. The company is developing TIL drugs, with its independently developed GT101 injection being the first TIL drug in China to obtain clinical registration. Currently, the GT101 injection is about to enter the critical phase II clinical trial stage.
Biotechnology
Synthetic Biology Company "Create Biotech" Completes Over RMB 100 Million in Series A Financing
Recently, Create Biotech Co., Ltd. (referred to as "Create Biotech") announced the completion of an A-round financing exceeding RMB 100 million, led by Source Code Capital, with co-investment from Bits x Bites and Sherpa Healthcare Partners, and Yuanqi Capital serving as the exclusive financial advisor.
The proceeds from this round of financing will be mainly used for Cytiva Biotech to expand the team, build a technology platform, and advance the product pipeline. Efficient R&D requires an excellent team, and successful product development relies on the support of advanced technology platforms. Cytiva Biotech will improve its synthetic biology technology platform integrated with automation, miniaturization, high-throughput, big data, and artificial intelligence, thereby accelerating the R&D of the product pipeline.
Cotya Biotech, founded in 2021, is a synthetic biology company dedicated to the research, development, production, and sales of high-value bio-based products. The company applies cutting-edge synthetic biology technology to provide natural, green, and sustainable innovative ingredient solutions for personal care, nutrition, pharmaceuticals, and other markets through advanced biomanufacturing. This helps society reduce reliance on petroleum while addressing various global issues such as environmental pollution, carbon emissions, and climate change.
.....
For overseas weekly financing events, recommended projects, and policy updates this week, see the full report.
----------------
*This is the simplified version of Pro Weekly Report*
To view the full report, please clickhttp://www.tmtpost.com/proBecome a Pro user of Titanium Media to view the complete "Titanium Media Pro Weekly Report"
"TMTBASE Database by Titanium Media" is an independent, precise, and efficient professional equity investment information platform under the Titanium Media Group, offering services including primary market research reports, enterprise data query services, equity crowdfunding project analysis services, and offline venture capital community services.
The report has been fully launched on the VIP Professional Edition of Titanium Media.Click the link Become a professional user of Titanium Media (http://www.tmtpost.com/pro), to obtain more investment and financing information services, more primary market research report businesses also include:Become a professional user of Titanium Media to read all professional content without limitation.